349 related articles for article (PubMed ID: 33884425)
1. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
Agrawal M; Zhang X; Brenner EJ; Ungaro RC; Kappelman MD; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1877-1884. PubMed ID: 33884425
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
3. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
4. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
[TBL] [Abstract][Full Text] [Related]
5. Introducing vedolizumab to clinical practice: who, when, and how?
Bryant RV; Sandborn WJ; Travis SP
J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
[TBL] [Abstract][Full Text] [Related]
6. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.
Adar T; Faleck D; Sasidharan S; Cushing K; Borren NZ; Nalagatla N; Ungaro R; Sy W; Owen SC; Patel A; Cohen BL; Ananthakrishnan AN
Aliment Pharmacol Ther; 2019 Apr; 49(7):873-879. PubMed ID: 30773667
[TBL] [Abstract][Full Text] [Related]
7. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.
Lamichhane N; Melas N; Bergqvist V; ; Ekholm NP; Olén O; Ludvigsson JF; Hjortswang H; Marsal J; Eriksson C; Halfvarson J
Dig Dis Sci; 2024 Jun; 69(6):2175-2183. PubMed ID: 38637457
[TBL] [Abstract][Full Text] [Related]
8. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.
Khan N; Pernes T; Weiss A; Trivedi C; Patel M; Medvedeva E; Xie D; Yang YX
Inflamm Bowel Dis; 2022 May; 28(5):734-744. PubMed ID: 34245261
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease.
Yung DE; Horesh N; Lightner AL; Ben-Horin S; Eliakim R; Koulaouzidis A; Kopylov U
Inflamm Bowel Dis; 2018 Oct; 24(11):2327-2338. PubMed ID: 29788385
[TBL] [Abstract][Full Text] [Related]
12. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
Chugh R; Long MD; Jiang Y; Weaver KN; Beaulieu DB; Scherl EJ; Mahadevan U
Am J Gastroenterol; 2024 Mar; 119(3):468-476. PubMed ID: 37796648
[TBL] [Abstract][Full Text] [Related]
13. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
[TBL] [Abstract][Full Text] [Related]
14. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
[TBL] [Abstract][Full Text] [Related]
15. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
Front Immunol; 2018; 9():1700. PubMed ID: 30131801
[TBL] [Abstract][Full Text] [Related]
16. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
[TBL] [Abstract][Full Text] [Related]
17. Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry.
Agrawal M; Brenner EJ; Zhang X; Colombel JF; Kappelman MD; Ungaro RC; ; Gearry RB; Kalpan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE
J Crohns Colitis; 2021 May; 15(5):860-863. PubMed ID: 33232456
[TBL] [Abstract][Full Text] [Related]
18. Effect of IBD medications on COVID-19 outcomes: results from an international registry.
Ungaro RC; Brenner EJ; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
Gut; 2021 Apr; 70(4):725-732. PubMed ID: 33082265
[TBL] [Abstract][Full Text] [Related]
19. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
Shmidt E; Kochhar G; Hartke J; Chilukuri P; Meserve J; Chaudrey K; Koliani-Pace JL; Hirten R; Faleck D; Barocas M; Luo M; Lasch K; Boland BS; Singh S; Vande Casteele N; Sagi SV; Fischer M; Chang S; Bohm M; Lukin D; Sultan K; Swaminath A; Hudesman D; Gupta N; Kane S; Loftus EV; Sandborn WJ; Siegel CA; Sands BE; Colombel JF; Shen B; Dulai PS
Inflamm Bowel Dis; 2018 Oct; 24(11):2461-2467. PubMed ID: 29788240
[TBL] [Abstract][Full Text] [Related]
20. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]